Special Guest · 8:00–8:15 AM PT
?
Special guest
Nadine Afari: peds park
Pitches · 8:15–9:30 AM PT
Centese, Inc.
Randy Preston, CEO · rpreston@centese.com
Intelligent Fluid Drainage for cardiac and thoracic surgery
Round
5,000,000 Convertible Note @ 20,000,000
Closed
N/A
FDA milestone
510(k) Clearance
FDA timeline
Cleared
Other groups in round
NYA, HBSAANY, MedTech Venture Partners
DD package
Yes
Traction: Revenue, 50 active customers, 20,000 procedures, multiple peer-reviewed publications
What they're looking for: KOLs
After the session
Investor sentiment
- High interest: 2
- Medium interest: 21
- Low interest: 1
- No interest: 7
Investor engagement
- Invitations to connect: 4
- Invitations to apply: 9
Medaica Inc.
Stephen Randall, CEO · stephen.randall@medaica.com
FDA-cleared, low-cost platform for early screening and detection of heart disease.
Round
$1M Post-money SAFE @ $20M
Closed
80% of $1M round committed
FDA milestone
FDA-cleared 510(k) Class II
FDA timeline
N/A - already cleared
Other groups in round
Management, Existing Investors and GEOD Nevada.
DD package
Yes
Traction: Emory Hospital Pilot, Belgrade Clinic Pilot, Accepted onto FSS for VA, Zoom Health endorsement
What they're looking for: Sales and Marketing Advisors with experience supporting VA and /or D2C funnels.
After the session
Investor sentiment
- High interest: 1
- Medium interest: 1
- Low interest: 5
- No interest: 24
Investor engagement
- Invitations to connect: 1
- Invitations to apply: 1
Aufero Medical
Daniel Gelman, CEO · dgelman@auferomedical.com
Round
$4M Seed Round Convertible Note @ $10M pre-money
Closed
$110K closed, $100K committed. Previously raised $1.01M total: $925K non-dilutive + $85K FF
FDA milestone
Clinical‑grade prototype completed; Preclinical validation demonstrating improved ablation, published in high-impact journals; Defined FDA Class II De Novo accessory pathway; Class II Health Canada pre-classification, submit investigational license soon.
FDA timeline
FDA De Novo submission: Q4-2027; Anticipated clearance: Q2-2028
Other groups in round
KF Matheson, Angel Investors Durham (Ontario, Canada); Strategic non‑equity collaborations with Abbott and Johnson & Johnson MedTech; Ongoing discussions with a prominent commercial EP player for potential strategic investment, including cash and in‑kind, player is an OEM manufacturer and U.S. distributor.
DD package
No
Traction: Strategic collaborations with Abbott and J&J MedTech (R&D and commercial); Principal investigators secured from Mayo Clinic and leading Canadian EP centers for clinical program; Shlomo Shpun (EP executive, medical officer) is on board; Kris Shah (Baylis, EP exit to BSX) committed investor; Since we are a catheter-agnostic enabler, many other EP companies expressed early interest (CardioFocus, Stereotaxis, Adagio, Field)
What they're looking for: Seed lead investor; Additional EP KOLs and advisors; Introductions to high‑volume EP labs; Strategic investors with EP portfolios
After the session
Investor sentiment
- High interest: 0
- Medium interest: 2
- Low interest: 12
- No interest: 11
Investor engagement
- Invitations to connect: 2
- Invitations to apply: 1